Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates
Globe Newswire•12/11/2026•16:00 ET
1
Key Highlights
- ➤$75 million Gilead collaboration extension fee received; cash runway projected into 2029
- ➤40% U.S. HSV program profit-share option exercised with Gilead
- ➤Phase 2 ABI-6250 study initiated in chronic hepatitis delta infection
- ➤Q3 net loss $20.3 million, or $0.93 per share, versus $9.2 million
- ➤Cash, equivalents and securities totaled $314.3 million at September 30
Expert Statements
Jason Okazaki, Chief executive officer and president of Assembly Bio
“This quarter, we rapidly advanced our liver disease program by initiating the Phase 2 study of ABI-6250 in chronic hepatitis delta virus and preparing for our Phase 2 study in cholestatic liver diseases, which we expect to begin in the first quarter next year.”
Jason Okazaki, Chief executive officer and president of Assembly Bio
“Alongside that progress, we elected to share U.S. costs and profits for the HSV helicase primase inhibitor program under our collaboration with Gilead, a decision we believe represents a significant opportunity to build long-term value.”
Jason Okazaki, Chief executive officer and president of Assembly Bio
“With a strong financial position, we look forward to the continued expansion of our pipeline and advancement of the herpesvirus and liver disease programs through their respective Phase 2 studies.”
– Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infection –
– Exercised 40% U.S. Profit-Share option for the HSV helicase primase inhibitor program –
Get started
Create a free account to read the full story.